acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorts still need millions of shares to cover.
Positive data from the MANF comparative study triples the share price overnight.
.20 by 12/31/2012.
"Big pharma" partnership(s)and licensing agreements takes it over a $1.00 in 2013.
The next press release could easily triple the share price.
MANF comparative study results expected any day now.
Obviously reading for comprehension wasn't one of your strong points in school.
Read my post. It in no way relates to comparing BONZ to NSRS.
I pointed out NSRS as an example of what could happen to the price of a penny stock based on a "pump" campaign. The intent was to point out that with many penny stocks there doesn't have to be a connect between reality and fabricated information. The NSRS "pump and dump" happened.
The same thing could happen with BONZ although I doubt if the company's management would have any involvement in it.
If BONZ's share price hits four cents then that would be fine with me.
.25 would be much better.
Wasting time posting on a board of a stock in which I have no position doesn't constitute my idea of a meaningful life.
Even if this gets deleted I'll know that Mike Long read it and hopefully got the message. That is one of the perks of being a board monitor.
Get a life Mike!!!
.15-.20 on 12/31/2012.
$1.00 or higher in 2013.
I'll side with the co-founder of Amgen and expect billion of dollars in future revenues. :)
License agreements for the MANF technology could provide billions in future revenues to the company from any number of major drug companies located throughout the world.
Why one "big pharma" partner when the company could have dozens of them.
p.s. .12-.15 by Friday. Higher if the comparative study data is released by then.
MANF comparative study results due out at any time.
The share price could easily double over night.
Add a few shares on the dips if they ever happen. :)
.20 by 12/31/2012 and up from there.
GLTA
Don't focus on .20 by 12/31.
Focus on $1.00 or higher when a "big pharma" development partnership is announced in 2013.
If the co-founder of Amgen states that the company's patented MANF technology is one of the best candidates that he's ever seen to generate billions of dollars in future revenues then I'm inclined to believe him and buy AMBS shares at the current depressed price.
I hope others are also taking advantage of the market not yet knowing about the tremendous upside that the company offers.
The current share price is "free" money.
Who's selling a $1.00 stock for five cents?
.20 on 12/31/2012
"Big pharma" development partnership in 2013 takes it to over $1.00.
Anyone selling/shorting here should get out of the market.
In all my years of investing I've only found a few obvious opportunities that offer the tremendous upside that AMBS offers in both the short and long term.
A penny downside versus $1.00 upside.
Exciting times ahead.
.15-.20 by the last day of the year.
Good luck to all.
AMBS will be the "2013 Stock of the Year" and the company will also possess the "2013 Bio-Tech C.E.O. of the Year".
Great times ahead for the shareholders.
Don't forget this upcoming event:
Amarantus Bioscience to Present at OneMedForum 2013
http://finance.yahoo.com/news/amarantus-bioscience-present-onemedforum-2013-125200574.html
I expect that this will the first of many investor conferences that the company participates in during 2013.
Based on recent events and realistic expectations going forward .15-.20 by 12/31/2012 is a reasonable price target.
The logical scenario of a "big pharma" development partnership or a buyout offer in 2013 would take this to $1.00 or higher.
Invest in additional shares accordingly.
2013 will be a very exciting year for the AMBS shareholders.
Don't be on the sidelines wondering why you didn't invest at the current low price. This is substantially undervalued.
Have a great day!!!
p.s. The next press release could easily triple the share price overnight.
Every time the penny-flippers sell and try to drop down and buy back in at a lower price they're losing out.
The word is getting out to the market about the tremendous upside that AMBS offers over both the short and long term.
.15-.20 by 12/31/2012.
"Big pharma" development partnership or buyout in 2013 takes this to a minimum of $1.00.
Interesting months ahead for the shareholders.
p.s. The MANF comparative study data should be out soon. Expecting a gap-up on the news.
I learned a long time ago that saying that something as unpredictable as a penny stock price would "never" happen is a good prescription for being wrong.
I could just as easily say that the share price will be above .04 on the day that the first gold revenues are reported and subsequently much higher if a partnership or joint venture is announced.
Interesting months ahead for the shareholders.
.06 when the first gold revenues are reported seems reasonable.
I'm thinking the first or second week of January.
Good luck to all the "BONZ" faithful both old and new.
P.s. Do you realize how rare it is for a "penny gold mining stock" to actually have the company start actual gold production? I'm thinking less than 1%.
There are a myriad of opportunities for Amarantus Bioscience moving forward.
This is so undervalued currently that I almost feel like I'm stealing shares every time I buy a few more.
"Big pharma" development partnership takes it above $1.00 in 2013.
It's my belief that many of the individuals that are posting here really don't appreciate the huge upside that the current share price offers.
The market is just finding out about AMBS.
The penny flippers will soon be left behind and the shorts will get burned badly.
News is getting out.
This is only one press release away from a substantial gap (500% overnight) higher.
.15-.20 on 12/31/2012.
.25-.30 by the end of January,2013.
Interesting months ahead for the shareholders.
The word is getting out to the market about the tremendous opportunity that exists for Amarantus Bioscience and its shareholders in the months and years ahead.
A "big pharma" partnership or buyout takes this to $1.00 in 2013.
Anyone selling for a penny or two profit now will regret it very soon.
Interesting time to be a shareholder in AMBS.
MANF study results due out any day now. Don't be on the sidelines when the news is released.
A very "Merry Christmas" and a very properous 2013 awaits all of us.
Posts that reference a reverse split are typically posted by someone who sold already and is trying to convince others to do so also so that they can try to buy back in at a lower price.
This should be at .15 by 12/31/2012 and heading higher.
The current share price substantially undervalues the company simply based on what we already know. There are numerous realistic scenarios that take this to the .50 range and then higher from there.
"Big pharma" development partnership or buyout in 2013 is one realistic scenario.
Price target: $1.00
Sanofi?
I'm expecting .15-.20 on 12/31/2012.
That would constitute a reversal.
IMHO.
Considering the quality individuals that have associated with the company in recent months I have to believe that the company's C.E.O. has already given thought to trying to bring Mr. Fox on board.
It were to happen it wouldn't be a surprise to me.
I am anxious to see who are next individuals to join the company either as directors or advisors.
Isn't it great to be here at the beginning?
I think it would be great news if the company were to get Michael J. Fox to join its board of directors.
I suspect the same thought has come to the company's C.E.O.
Interesting months ahead for the company and its shareholders.
I'm expecting a partnership or joint venture announcement by the end of the first quarter/2013.
Three months of gold production by then. Up sizing to the Alaskan-25 unit at that time.
Connect the dots.
"Big pharma" development partnership or buyout in 2013.
$1.00 price target may be on the low side.
Management's plan is on tract.
AMBS will be one of the top performing stocks in 2013.
Imagine how fortunate it is that you are reading this before the market discovers the tremendous upside that the company offers and you can still buy shares under .10.
Interesting months ahead for the shareholders.
Ask yourself a simple question:
"How high will the share price go when a "big pharma" development partnership or a buyout is announced?"
Risk/reward says to buy shares at the current price.
It's the best opportunity in the market to make substantial profits heading into 2013.
2,500% upside?
Consider who the individuals are that are associating themselves with the company.
Due diligence begins there.
MANF comparative study results due out next week.
Shorts are working hard to keep this down today.
This should be trading in the .15-.20 range currently.
The market is gradually catching up.
I agree 100%. This could create substantial wealth for a lot of smart investors.
$50,000 invested today could be worth over $1,000,000 in less than a year.
You're assessment is potentially correct.
I tend to be a bit on the conservative side.
The company's management is doing a lot of things right.
The one thing I do believe is that anyone who is selling/shorting here will regret it in a few weeks.
You've got the "2013 Stock of the Year" and the "2013 Bio-Tech C.E.O. of the Year" right in front of you.
I hope you'll take advantage of having this information now before the market discovers the upside that the company offers.
How many times have you missed buying a stock at the bottom?
I'm holding until the partnership or buyout happens.
GLTA
I think $1.00 is realistic. Obviously I'd welcome a higher price for my shares.
This will be above .15 within three weeks and headed higher.
Most undervalued bio-tech in the market.
2013 will be a very exciting and profitable year for the company and its shareholders.
"Big pharma" partnership or buyout is a very realistic scenario.
MANF comparative study data next week. 100% upside on the news.
Buy a few shares today.
$1.00 price target for 2013 says "Stocktipster".
.20 on 12/31/2012.
More great news on the way. :)
"Big pharma" partnership or buyout in 2013 will take the share price to the $1.00 range.
The quality of individuals associating with the company (i.e. co-founder of Amgen) demonstrates the real potential that exists here.
Unfortunately many individual will sell for a 25% profit and miss the 2,500% profit (based on yesterday's closing price) that will be reached when the "key" event occurs.
.20 on 12/31/2012. Comparative study data out before then.
Shorts are on the wrong side of where this is headed and they need millions of shares to cover.
2013 will be a very "Happy New Year" for the shareholders.
"Big pharma" development partnership or buyout in 2013.
Major drug companies are flush with cash and facing the "patent cliff" for many of their major revenue producing drugs.
$1.00 price target.
"2013 Stock of the Year" and "2013 Bio-Tech C.E.O. of the Year" are right in front of you.
A very "Merry Christmas" and a very, very, prosperous 2013 for the shareholders.
p.s. This is setting up for a major short squeeze.
Comparative study results out next week.
Expecting .12-.15 by next Friday.
A very "Merry Christmas" for all the shareholders.
A penny downside versus $1.00 upside.
Buy/cover before the serious move higher begins.
A very "Merry Christmas" and a prosperous "New Year" ahead for the shareholders.
"Big pharma" development partnership or a buyout in 2013.
Last day below four cents. Gap up tomorrow.
Today may be the last day under four cents.
This is overdue for a substantial gap higher as the date for the results of the comparative study draws nearer.
Due for another positive press release.